Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with carbon-ion radiotherapy and weekly cisplatin for locally advanced cervical cancer
jRCT2031210083Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and cisplatin in Cervical Cancer (CC), sponsored by AstraZeneca. Primary endpoint: Adverse events, serious adverse events, and dose-limiting toxicities. Started Dec 2021; status: completed.
02
Drugs
durvalumabcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2031210083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210083.